AI assistant
Sending…
Tango Therapeutics, Inc. — Director's Dealing 2021
Nov 1, 2021
32459_dirs_2021-11-01_2472a5c6-05e2-4068-ad5c-11380c8c4bd2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Tango Therapeutics, Inc. (TNGX)
CIK: 0001819133
Period of Report: 2021-10-18
Reporting Person: Rudoltz Marc (Chief Medical Officer)
More from Tango Therapeutics, Inc.
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 8
Annual Report
2026
Apr 17
Proxy Solicitation & Information Statement
2026
Apr 17
Regulatory Filings
2026
Apr 15
Director's Dealing
2026
Mar 28
Regulatory Filings
2026
Mar 25
Director's Dealing
2026
Feb 27
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17